Downregulation of ARL4C with siRNA and antisense oligonucleotides (ASOs), such as ASO-1316, is investigated in preclinical research for the treatment of lung adenocarcinoma (Kimura et al., 2020), liver cancer (Harada et al., 2019), and colorectal cancer (Fujii et al., 2015). This evidence concerns the gene ARL4C and lung adenocarcinoma.